David C. Stump M.d

Biography

Dr. David C. Stump, also known as Dave, M.D. served as an Executive Vice President of Research and Development at Human Genome Sciences Inc., since December 2003. Dr. Stump has more than 25 years of experience. His career in the biotechnology industry spans more than 20 years. Dr. Stump served as Executive Vice President of Drug Development at Human Genome Sciences Inc. from December 2003 to May 2007 and served as Senior Vice President of Drug Development from November 1999 to December 2003. He joined Human Genome Sciences Inc. in October 1999. He served as Vice President of Clinical Research and Genentech Fellow at Genentech Inc. from 1989 to October 1999. Dr. Stump first joined Genentech in 1989 as Director of Clinical Research and leader of its thrombolytic therapy drug development program. He has been an Independent Director of Sunesis Pharmaceuticals, Inc., since June 2006. He has been a Director of Portola Pharmaceuticals, Inc. since September 24, 2015 and MacroGenics, Inc. since September 18, 2013. He has been an Independent Director at Regenxbio Inc. since October 15, 2015. He serves as Board of Trustees for Adventist HealthCare Inc. and Earlham College. He served as a Director of Dendreon Corp. from June 2010 to June 10, 2015. He served as an Associate Professor of Medicine and Biochemistry at the University of Vermont. He is the Author of approximately 60 scientific publications. He is board certified in Internal Medicine, Hematology and Medical Oncology and is a Fellow of the American Colleges of Physicians and the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association. Dr. Stump holds an A.B. from Earlham College and an M.D. at Indiana University, followed by residency and fellowship training in internal medicine, hematology and oncology and biochemistry at the University of Iowa. He completed postgraduate training in hemostasis and thrombosis at the University of Leuven, Belgium

Research Interest

Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. The company’s mid- and early-stage pipeline products comprise Mapatumumab, a human monoclonal antibody for the treatment of advanced hepatocellular cancer